BIOC - Biocept, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.34
-0.05 (-2.09%)
At close: 4:00PM EDT

2.34 0.00 (0.00%)
After hours: 5:41PM EDT

Stock chart is not supported by your current browser
Previous Close2.39
Open2.38
Bid2.25 x 1000
Ask2.66 x 1100
Day's Range2.31 - 2.54
52 Week Range2.19 - 37.50
Volume184,383
Avg. Volume224,628
Market Cap6.844M
Beta (3Y Monthly)0.25
PE Ratio (TTM)N/A
EPS (TTM)-15.44
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.13
Trade prices are not sourced from all markets
  • Biocept to Present at The MicroCap Conference in New York on October 2
    PR Newswire21 days ago

    Biocept to Present at The MicroCap Conference in New York on October 2

    SAN DIEGO , Sept. 25, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to ...

  • Biocept Awarded Patent in Hong Kong for its Target Selector Platform Using Antibodies and a Microchannel to Perform Liquid Biopsy
    PR Newswire22 days ago

    Biocept Awarded Patent in Hong Kong for its Target Selector Platform Using Antibodies and a Microchannel to Perform Liquid Biopsy

    The issued patent covers the use of antibodies for the capture of any cell of interest, including circulating tumor cells (CTCs), within a microchannel. "The granting of this patent further expands globally Biocept's intellectual property protection for capturing and detecting any cell of interest," said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept.

  • Biocept Announces Pricing of $2.5 Million Registered Direct Offering Priced at Market
    PR Newswire25 days ago

    Biocept Announces Pricing of $2.5 Million Registered Direct Offering Priced at Market

    SAN DIEGO, Sept. 21, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.5 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and concurrent private placement at market. The combined purchase price for one share of common stock (or one pre-funded warrant to purchase common stock in lieu thereof) and each warrant will be priced at $3.285.

  • Biocept Names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer
    PR Newswirelast month

    Biocept Names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer

    SAN DIEGO, Sept. 10, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the appointment of Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer. Mr. Hendrick brings to Biocept over 25 years of sales and commercial leadership experience in the healthcare industry, with recent senior level commercial and operational positions in the clinical diagnostics segment. "Edwin's outstanding experience developing successful commercial organizations in early-stage companies is a natural fit for Biocept, as we aim to continue to build our market presence in the emerging liquid biopsy segment," said Michael Nall, President and Chief Executive Officer of Biocept.

  • Biocept's Target Selector Platform Featured in Two Poster Presentations at the IASLC 19th World Conference on Lung Cancer
    PR Newswirelast month

    Biocept's Target Selector Platform Featured in Two Poster Presentations at the IASLC 19th World Conference on Lung Cancer

    SAN DIEGO, Sept. 6, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that two poster presentations featuring clinical data sets using its Target Selector™ liquid biopsy platform will be presented at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer. The conference is being held September 23-26, 2018 in Toronto at the Metro Toronto Convention Centre.

  • Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer
    PR Newswire2 months ago

    Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer

    Allegheny Health Network's Cancer Institute spearheading the evaluation PITTSBURGH and SAN DIEGO , Aug. 23, 2018 /PRNewswire/ -- Highmark Health announced today that through its VITAL Innovation Program, ...

  • Benzinga2 months ago

    The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 14) DexCom, Inc. (NASDAQ: DXCM ) Masimo Corporation (NASDAQ: MASI ...

  • Biocept Reports Second Quarter 2018 Financial Results
    PR Newswire2 months ago

    Biocept Reports Second Quarter 2018 Financial Results

    Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , Aug. 14, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to ...

  • Biocept to Release Second Quarter 2018 Financial Results and Host Investor Conference Call on August 14, 2018
    PR Newswire2 months ago

    Biocept to Release Second Quarter 2018 Financial Results and Host Investor Conference Call on August 14, 2018

    SAN DIEGO , Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable ...

  • Biocept Announces $11.6 Million in Expected Gross Proceeds from Recently Expired Rights Offering
    PR Newswire2 months ago

    Biocept Announces $11.6 Million in Expected Gross Proceeds from Recently Expired Rights Offering

    SAN DIEGO, Aug. 9, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announced today that the Company's previously announced rights offering (the "Rights Offering") expired on Wednesday, August 8, 2018 and these rights are no longer exercisable. The Company accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $11.6 million in gross proceeds.

  • Biocept Announces Agreement with Managed Care Plan to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs
    PR Newswire2 months ago

    Biocept Announces Agreement with Managed Care Plan to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs

    SAN DIEGO, Aug. 6, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered into an agreement with a large integrated healthcare delivery network to evaluate the clinical utility and cost effectiveness of using Biocept's Target Selector™ testing in patients diagnosed with non-small cell lung cancer (NSCLC). As part of the agreement, the Company's liquid biopsy testing will be used to profile patients who have been diagnosed with NSCLC and/or have progressed on EGFR targeted therapy.

  • Biocept Awarded Patent in Canada for its Target Selector CTC Platform
    PR Newswire2 months ago

    Biocept Awarded Patent in Canada for its Target Selector CTC Platform

    Further expands global patent estate for capturing and detecting biological targets of interest including rare cells such as circulating tumor cells (CTCs) SAN DIEGO , Aug. 2, 2018 /PRNewswire/ --  Biocept, ...

  • European Patent Granted for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Platform
    PR Newswire3 months ago

    European Patent Granted for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Platform

    The patent provides intellectual property protection in seven European countries and is core to Biocept's Target Selector™ assays for ctDNA analysis using real-time PCR, Sanger sequencing and next-generation sequencing (NGS).

  • Biocept and UC San Diego Moores Cancer Center Announce Collaboration to Study Feasibility of Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy
    PR Newswire3 months ago

    Biocept and UC San Diego Moores Cancer Center Announce Collaboration to Study Feasibility of Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy

    SAN DIEGO, July 23, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will work with Moores Cancer Center at UC San Diego Health to conduct two clinical studies in patients with a variety of solid tumors.

  • Biocept Reminds Investors of Today's Deadline to be a Shareholder of Record
    PR Newswire3 months ago

    Biocept Reminds Investors of Today's Deadline to be a Shareholder of Record

    SAN DIEGO, July 19, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today issued a reminder to shareholders that the record date of its proposed rights offering is Monday, July 23, 2018. To be a shareholder of record on the record date, ownership of Biocept stock must occur by market close on Thursday, July 19, 2018 to account for settlement.

  • Biocept, Inc. (BIOC) Soars: Stock Adds 9.8% in Session
    Zacks3 months ago

    Biocept, Inc. (BIOC) Soars: Stock Adds 9.8% in Session

    Biocept (BIOC) was a big mover last session, as the company saw its shares rise more than 9% on Friday amid huge volumes.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Stocks to Watch: Biocept and Johnson and Johnson

    NEW YORK, NY / ACCESSWIRE / July 16, 2018 / Johnson & Johnson shares saw a drop on Friday as traders reacted to last week’s court decision that the company owes $4.69 billion to 22 women over its talc-based products allegedly causing them cancer. The company is vehement on appealing the court order. Biocept shares were skyrocketing on an announcement that it has entered into an agreement with Alliance Global FZ to market and distribute liquid biopsy testing in the Middle East, Southeast Asia, and the Africa region.

  • Why RH, Biocept, and Lowe's Jumped Today
    Motley Fool3 months ago

    Why RH, Biocept, and Lowe's Jumped Today

    One of these companies said investors shouldn't worry about proposed China tariffs.

  • Why Biocept’s Stock Price Is Soaring Today
    Market Realist3 months ago

    Why Biocept’s Stock Price Is Soaring Today

    Today, Biocept (BIOC) is trading at a stock price of $10.72, which represents ~63.66% growth from yesterday’s close of $6.55.

  • InvestorPlace3 months ago

    BIOC: What’s Going on With Biocept Stock?

    Biocept stock (NASDAQ:BIOC) was skyrocketing on Friday as the company announced a biopsy testing partnership with Alliance Global FZ. Biocept’s bread and butter is the development and administration of liquid biopsy tests that allow physicians to amass clinically actionable information to help improve the outcomes of patients who have been diagnosed with cancer. The company has inked a deal with Alliance Global to market and distribute Biocept’s Target Selector liquid biopsy tests.

  • Why Biocept, Inc. Is Rebounding Big-Time Today
    Motley Fool3 months ago

    Why Biocept, Inc. Is Rebounding Big-Time Today

    The molecular diagnostics company inked a new distribution deal that helped investors forget yesterday's bad news.

  • Benzinga3 months ago

    Biocept Rallies On Marketing Agreement For Proprietary Liquid Biopsy Tests

    Biocept Inc (NASDAQ: BIOC ) shares were ripping higher Friday following the announcement of a provider agreement with Alliance Global. The stock was rallying 58.32 percent to $10.31 at the time of publication.  ...

  • Biocept Enters into Agreement with Alliance Global FZ to Market and Distribute Liquid Biopsy Testing in the Middle East, Southeast Asia, and Africa Region
    PR Newswire3 months ago

    Biocept Enters into Agreement with Alliance Global FZ to Market and Distribute Liquid Biopsy Testing in the Middle East, Southeast Asia, and Africa Region

    SAN DIEGO, July 13, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces a provider agreement with Alliance Global FZ, LLC to market and distribute Biocept's Target Selector™ liquid biopsy tests in the United Arab Emirates and select countries in the Middle East, North & Sub-Saharan Africa, and Southeast Asia (MEAA) region. All diagnostic testing services under this agreement will be performed in Biocept's San Diego-based CLIA-certified laboratory with Alliance Global having responsibility for sales, marketing, distribution, and reimbursement of the Company's liquid biopsy platform.

  • Why Biocept, Inc. Stock Is Plunging Today
    Motley Fool3 months ago

    Why Biocept, Inc. Stock Is Plunging Today

    Shares of the small molecular diagnostics specialist took a beating after it announced an infrequently used method to raise cash.

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Biocept and Myriad Genetics

    NEW YORK, NY / ACCESSWIRE / July 12, 2018 / U.S. equities saw losses on Wednesday, breaking a winning streak of four consecutive days, as trade tensions grew following the White House's announcement of ...